Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Cancer Metastatic × Ipilimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 208 Carcinoma, Non-Small-Cell Lung 65 Carcinoma, Renal Cell 54 Neoplasm Metastasis 44 Neoplasms 36 Prostatic Neoplasms 31 Uveal Melanoma 25 Lung Neoplasms 23 Carcinoma, Hepatocellular 23 Pancreatic Neoplasms 22 Sarcoma 20 Colorectal Neoplasms 20 Breast Neoplasms 20 Brain Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 17 Small Cell Lung Carcinoma 17 Skin Neoplasms 16 Kidney Neoplasms 16 Carcinoma, Transitional Cell 15 Ovarian Neoplasms 14 Diabetes Mellitus, Insulin-Dependent, 12 14 Uterine Cervical Neoplasms 12 Urinary Bladder Neoplasms 12 Triple Negative Breast Neoplasms 12 Mesothelioma 11 Stomach Neoplasms 10 Recurrence 10 Multiple Myeloma 10 Head and Neck Neoplasms 10 Lymphoma, Non-Hodgkin 9

Interventions

tremelimumab 1 regramostim 1 osimertinib 1 evolocumab 1 durvalumab 1 Radiotherapy 1 Radiation 1 Nivolumab 1 MLN 8237 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡